US Nuclear Corp (OTC: UCLE) has reported a 72% reduction in loss from operations for the first quarter of 2026, compared to the same period last year, according to its recently filed quarterly report. The company, which filed its US Nuclear Form 10Q_March 31, 2026, reduced its operating loss by over $375,000, signaling a significant turnaround in its core business performance. However, the filing comes months after its deadline, and the company's stock will not resume trading until after the release of its third-quarter results, projected for early December.
The delay stems from a series of operational and reporting challenges that began with the closure of its Los Angeles facility. According to CFO Michael Hastings, the company lost key personnel following the closure, which made retrieving financial data more difficult. Additionally, the company replaced some staff at its Overhoff subsidiary, and a new auditor recommended changes that took time to implement. The 2025 audit process stretched much longer than expected, pushing subsequent quarterly filings past their deadlines. The first-quarter close and review alone took about four months, far exceeding the 45-day window. Hastings noted that the company is committed to making the reporting process faster and more efficient, and is working diligently with its internal team and independent auditors to finalize the second-quarter filing as quickly as possible.
Despite these setbacks, US Nuclear has taken several steps that management believes will make 2027 a record year. In June, the company engaged a skilled General Manager/COO who is already streamlining logistics, clearing backlogs, and accelerating product and service delivery, thereby improving the working capital cycle. The company's backlog has grown to $1.2 million and is expected to reach $2.9 million by year-end. US Nuclear is also interviewing outsourced CPA firms to ensure timely and accurate financial reporting, with onboarding expected imminently. Furthermore, the GM is utilizing four college interns to conduct a full marketing and product analysis of the TA/Optron product line, which was previously built in Los Angeles. The goal is to re-launch these products in January 2027, with hopes of adding $600,000 in revenues that year.
In addition to organic growth initiatives, US Nuclear has started discussions with other companies this summer regarding potential joint ventures, a sale of the company to a larger entity, or a reverse merger with a synergistic company interested in going public. Management expects 2027 sales and profits to increase 20-30%, and sales to double the current level in 2028, or significantly higher if a transaction is completed in 2027. These projections, while forward-looking, underscore the company's confidence in its operational improvements and strategic options.
The implications of this announcement are twofold. First, the substantial reduction in operating loss demonstrates that US Nuclear's cost-cutting and restructuring efforts are yielding tangible results, which could attract investor attention once the stock resumes trading. Second, the delayed filings and the need for a new auditor highlight ongoing internal control weaknesses that the company must address to regain market confidence. For a small-cap company like US Nuclear, timely and accurate financial reporting is critical for maintaining credibility and access to capital. The company's ability to execute on its backlog, re-launch the TA/Optron line, and potentially secure a strategic transaction will determine whether it can achieve its ambitious 2027 targets. Investors and stakeholders will be watching closely for the second- and third-quarter filings, as well as any updates on the joint venture or merger discussions. The full details of the company's financial condition are available in its US Nuclear Form 10K_December 31, 2025 and the recent 10Q.
